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Abstract
Background: Screening women for Chlamydia trachomatis infection in developing countries is highly desirable
because of asymptomatic infection. The existing diagnostic methods in developing countries are not effective and
their sensitivity fall below 45.0% which leads to further spread of infection. There is an urgent need for improved
and cost effective diagnostic tests that will reduce the burden of sexually transmitted infections in the developing
world.
Methods: Prevalence of C. trachomatis infection among women visiting gynaecology department of Hindu Rao
hospital in Delhi, India was determined using Roche Amplicor Multi Well Plate kit (MWP) as well as using in-house
PCR assay. We used 593 endocervical swabs for clinical evaluation of the in-house developed assay against Direct
Fluorescence Assay (DFA; Group I n = 274) and Roche Amplicor MWP kit (Group II, n = 319 samples) and
determined the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of the in-
house developed assay.
Results: We detected 23.0% positive cases and there was a higher representation of women aged 18-33 in this
group. An in-house PCR assay was developed and evaluated by targeting unique sequence within the gyrA gene
of C. trachomatis. Specificity of the reaction was confirmed by using genomic DNA of human and other STI related
microorganisms as template. Assay is highly sensitive and can detect as low as 10 fg of C. trachomatis DNA. The
resolved sensitivity of in-house PCR was 94.5% compared with 88.0% of DFA assay. The high specificity (98.4%) and
sensitivity (97.1%) of the in-house assay against Roche kit and availability of test results within 3 hours allowed for
immediate treatment and reduced the risk of potential onward transmission.
Conclusions: The in-house PCR method is cost effective (~ 20.0% of Roche assay) and hence could be a better
alternative for routine diagnosis of genital infection by C. trachomatis to facilitate improved screening and
treatment management.
Background
Genital infection due to Chlamydia trachomatis is one of
the most common sexually transmitted infections.
Worldwide, an estimated 92 million new cases of C. tra-
chomatis infection occur each year. More than two-thirds
of these cases occur in the developing world, where diag-
nostic and treatment services are almost absent [1].
Asymptomatic (nearly 80.0% of women and 40.0% of
men) [1] and untreated genital infections have serious
ramifications for the reproductive health of women as it
may evolve into complications such as ectopic pregnancy,
pelvic inflammatory disease, salpingitis with tubal scar-
ring and infertility in female patients [1-3]. In infected
men, arthritis and epididymitis may result in urethral
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tract infection is an important risk factor for human
papillomavirus induced cervical neoplasia as well as
human immunodeficiency virus (HIV) transmission
[4-6]. Undiagnosed and untreated chlamydial infections
are thus not only creating major health problems and
consequences for individuals but also result in major epi-
demiological, social and economical problems. The
developing countries have a high incidence of new chla-
mydial infection, however, with the exception of sporadic
testing, screening for Chlamydia is rare. Using various
diagnostic tests with different performance characteris-
tics, the prevalence of chlamydial infection among
women in developing countries specifically sex workers
varies from 8.5% to 37.0% [7-10]. The prevalence among
female sex workers ranged from 27.0-36.0% in Philip-
pines [11,12] while it is 24.0% in Indonesia [7].
The prevalence of sexually transmitted diseases could
be as high as 17.6% among females from tribal population
[13] to varying degree in metropolitan cities in India [14].
The incidence of chlamydial infection in female sex
workers in Surat was estimated to be 8.5% using PACE2
test (non-amplified DNA probe assays for C. trachomatis
and N. gonorrhoeae; Gen-probe San Diego, USA) while in
Ahmedabad it was almost double [8]. Although national
screening programmes are in place in developed coun-
tries, such programmes are non-existent in most of the
developing countries even among high risk population
such as sex workers. Consequently for symptomatic
patients WHO recommends a syndromic approach to
case management [15] but unnecessary treatment is the
major disadvantage of syndromic management. The
major limitation for screening programmes is the lack of
simple and cost effective diagnostic tests. Intracellular
localization of the pathogen creates an additional chal-
lenge for routine diagnosis. Diagnosis of chlamydial
infection is even more difficult in asymptomatic and in
chronic or persistent infections where the pathogen load
would be low. The large pools of asymptomatic infected
people are not only at the risk of developing serious
long-term sequelae but would also transmit the infection.
Urdea et al., speculated that approximately 3 million vic-
tims suffering from Disability Adjusted Life Years
(DALYs) can be saved, more than 12 million incidence of
gonorrhoea and Chlamydia infections can be averted,
about 161,000 HIV infections can be prevented among
female commercial sex workers in sub-Saharan Africa,
China and Southeast Asia with a diagnostic method that
requires minimal laboratory infrastructure but has 85.0%
sensitivity and 90.0% specificity for both gonorrhoea and
Chlamydia [16]. A test that requires no laboratory infra-
structure could save ~4 million DALYs, avert >16.5 mil-
lion incidence of gonorrhoea and Chlamydia infections
and prevent >212,000 HIV infections [16].
Nucleic acid amplification test (NAATs) are the tests
of choice for the diagnosis of C. trachomatis genital
infections because of their high sensitivity, specificity
and suitability for various types of sample, including vul-
vovaginal swabs and first void urine (FVU), [3,14,17].
NAAT has also facilitated the use of less invasive proce-
dures for detection of asymptomatic C. trachomatis
infection in female patients. Several commercial NAATs
a r ea v a i l a b l ea n dt h e ym a k eu s eo fd i f f e r e n tt e c h n o l o -
gies: conventional PCR; quantitative PCR (Roche Diag-
nostics, Abbott IL, USA); strand displacement
amplification (Becton Dickinson, NJ, USA); transcrip-
tion-mediated amplification (Gen Probe) and nucleic
acid sequence-based amplification (Bio Merieux, Nancy
L’Etoile, France). The high cost of these kits and lack of
appropriate infrastructure are the major deterrents for
using these kits for large screening programmes to be
conducted in developing countries including India. The
principal detection methods of C. trachomatis infections
in India still remain to be the culture method and Direct
Fluorescent Assay (DFA). In addition, most of the
resource limited clinics continue to practice syndromic
management. Therefore there is a paucity of information
regarding epidemiology of STD including C. trachomatis
infections in India. However, considering the high pre-
valence of infection in India there is an urgent need to
design tests that are simple, inexpensive and can be
used to improve diagnosis as well as specificity of the
syndromic management [18-21].
In the present, study we have designed and established
a simple PCR based assay for diagnosis of C. trachoma-
tis using primers against genomic sequences. The eva-
luation of the test for its specificity, sensitivity, positive
and negative predictive values against currently used
diagnostic methods suggest that in-house PCR assay is
highly comparable in its performance to that of com-
mercial kits and is considerably less expensive. Availabil-
ity of the test result within few hours could allow
treatment at the initial visits and helps in preventing
further transmission of the disease.
Methods
Enrolment of Patients
Total 593 out of the 2800 patients (median age 29 years
and aged between 18-60 years), visiting gynaecology
department, were enrolled for the study. Enrolment of
patient was determined on the basis of vaginal discharge
and other STD related symptoms. All participants were
informed and oral consent of patients was taken.
Specimen collection
A thorough vulval examination was done for lesions and
vaginal/cervical discharge. Perspeculum examination was
carried out for wart, erosions and abnormal growth by
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swab (Hi Media, Mumbai, India), two endocervical
swabs were taken from each patient. In order to avoid
swab sample variation that can occur when multiple
swabs are taken, the clinical samples were divided into
two groups (I & II). In the first group of 274 samples,
sterile cotton swab was used to collect each specimen in
1 ml transport medium [22]. The specimen from second
swab was smeared on a clean glass slide, air-dried for
DFA and Fluorescence in-situ hybridization assay
(FISH). For the second group of 319 samples, two endo-
cervical swab specimens were obtained. The first swab
was placed in a vial containing AMPLICOR Specimen
Transport Medium of Roche and the second swab was
placed in 1 ml transport medium. All samples were kept
on ice and tested within 24 hours or stored at -80°C for
subsequent use.
Primer designing
Sequences of four genes of C. trachomatis were
obtained from Gene Bank. The selected sequences were
Glucosamine-Fructose-6-phosphate Aminotransferase
(gfa) (CT816, Entrez Gene ID: 884625), hypothetical
protein (CT163, Entrez Gene ID: 884039), Phospholi-
paseD Endonuclease (plde) Superfamily (CT157, Entrez
Gene ID: 884104) and gyrA gene (CT189, Entrez Gene
ID: 884941), producing an amplicon of size 145-bp, 418-
bp, 368-bp and 463-bp respectively. Short stretches of
about 25-30 nucleotides were aligned using the BLAST
program http://blast.ncbi.nlm.nih.gov/ from NCBI to
assess potential cross-reactivity with other organisms.
Sequences unique to C. trachomatis were selected for
primer designing using Gene Runner 3.05. The selected
primers of gyrA (CT189) are as follows: Forward primers
C2- 5′ TGATGCTAGGGACGGATTAAAACC 3′,T m
63.7°C, Reverse primer C5- 5′ TTCCCCTAAAT-
TATGCGGTGGAA 3′, Tm 64°C. (Indian patent number
239908; US, UK, EU patent pending).
PCR Amplification
For PCR assay, specimens were processed by lysis
method as described previously [22]. Supernatant (5 μl)
of processed sample or crude lysate was used for PCR
in a reaction volume of 25 μlc o n t a i n i n g1 ×T a qD N A
p o l y m e r a s eb u f f e r( 5 0m MK C l ,1 0m MT r i s - H C lp H
8.3, 1.5 mM MgCl2), 200 μM each of the four dNTPs
(New England Biolabs Inc, Beverly, MA, USA), 10
pmoles each of forward and reverse primers, 0.7 U of
Taq DNA polymerase (Bangalore Genei India Pvt. Ltd.,
Bangalore, India). Purified genomic DNA of C. tracho-
matis (kindly provided by Lynn Olinger, Francis I. Proc-
tor Foundation, University of California, San Francisco)
was used as a positive control for each set of assays.
Amplification was performed using thermal cycler
(I cycler, Bio-Rad, Richmond, USA) for 35 cycles; 95°C
for 5 min for initial denaturation, followed by 35 cycles
of 95°C for 30 sec, 60°C for 30 sec, 72°C for 1 min, final
extension at 72°C for 5 min. The amplicons were ana-
lyzed on 1.5% agarose gel by electrophoresis. The ampli-
cons from ten percent of positive samples were eluted
using a DNA isolation kit (Biological Industries Ltd.,
Kibbutzbeit Haemek, Israel) according to the manufac-
turer′s instructions and sequenced using PCR primers
(forward primer) with a Taq-Dye terminator cycle
sequencing kit on 377A autosequencer (Applied Biosys-
tems, California, USA) at TCGA (IGIB) India. DNA
sequence of the amplified product was compared to
known gyrA nucleotide sequences (Jan, 2009) in the
GenBank databases using BLAST program to determine
the percent identity.
Roche AMPLICOR MWP Chlamydia trachomatis Detection
Assay
Three hundred and nineteen endocervical specimens of
group II were tested by Roche AMPLCOR CT detection
kit (Roche Diagnostic Systems) according to the manu-
facturer’s instructions. For endocervical specimens, 1 ml
of specimen lysis buffer was added to endocervical sam-
ples, mixed thoroughly by vortexing and were incubated
for 10 min at room temperature. After overnight storage
at 4°C, 50 μl of the clinical sample was added to each
PCR tube containing 50 μl of PCR master mix. The
PCR master mix contained primers for internal control
as well. The assay was developed as per instructions
given by manufacturers. Samples for which the two
methods described above showed discrepancy, genomic
DNA was isolated from the aliquots of frozen speci-
mens. Samples were centrifuged at 15,000 × g for 30
min. Pellet was resuspended in 500 μl of lysis buffer
(Tris EDTA 50 mM pH 8.0, Proteinase K 400 μg/ml)
and incubated at 55°C for two hours and then boiled at
100°C for 10 min with 1 mM DTT. Thereafter DNA
was extracted with phenol:chloroform and centrifuged at
12,000 × g for 10 min, DNA was precipitated with iso-
propanol in the presence of 0.3 M sodium acetate and
incubated overnight at -20°C. Pellet was collected by
centrifugation at 12,000 × g for 10 min, washed with
70% ethanol, air-dried and dissolved in PCR grade water
[22].
Evaluation of specificity and sensitivity
To evaluate the specificity of the primer pair, DNA
extracted from positive controls, pathogens causing STI
and those representing general microflora of cervix were
used as templates in PCR reaction (Table 1). DNA was
extracted from these microorganisms as described
above. Ten human genomic DNA samples were also
used to evaluate the specificity of primer pair. To
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mic DNA from C. trachomatis at 100 pg to 1 fg concen-
trations following serial dilutions and various dilutions
of C. trachomatis positive clinical samples were used as
the templates for PCR amplification. All assays were
repeated at least five times. For clinical samples, repeat
assays were performed for randomly selected samples.
Direct Fluorescence Assay
For DFA (MicroTrak, Co Wicklow, Ireland), specimens
were centrifuged at 3000 × g for 10 min and pellets
were air dried, fixed by incubation in methanol and
stained with a fluorescein isothiocyanate-conjugated
anti-MOMP monoclonal antibody. The slides were
examined for typical apple-green fluorescent elementary
bodies (EBs) at 1000× magnification. The presence of
more than ten fluorescent EBs was scored as a positive
case.
Fluorescence In-situ Hybridization
FISH assay was performed as described previously [23].
Definition of a positive sample
All 274 clinical specimens in group I were tested by
DFA and in-house PCR. FISH assay was carried out on
discrepant results as a confirmatory test. Samples were
considered positive if they tested positive by any of the
two methods. All 319 clinical specimens of Group II
were tested by Roche Amplicor MWP kit and by the
in-house PCR assay. Amplification of known C. tracho-
matis genes ompA (CT681; Entrez GeneID: 884473)
and plde (CT157, Entrez Gene ID: 884104) were car-
ried out on discrepant samples. Samples were consid-
ered positive if they tested positive by at least two PCR
methods: Roche Amplicor MWP kit/in-house PCR/
PCR amplification of ompA or plde gene. The preva-
lence of C. trachomatis infection was determined
based on the total number of positive samples after
discrepant analysis.
DATA analysis
All statistical analysis was performed using GraphPad
Prism version 5.03 software. Sensitivity, specificity, PPVs
and NPVs were calculated with 95% confidence intervals
to test the significance.
Results and Discussion
The cardinal sign for chlamydial infection according to
syndromic case management guidelines is discharge
from the cervix. Out of 2800 female patients who visited
the gynaecology department for reproductive health pro-
blems and contraception, 593 patients were enrolled for
this study. Almost all participants were symptomatic,
including vaginal discharge (58.0%), lower abdominal
Table 1 List of various organisms and their source; used for evaluation of specificity of the C2/C5 primers
Organism/Strain/Isolate Number of
Specimens tested
Source(s)
C. trachomatis serovar L2 1 Dr. Peter Braun, Max Plank Institute for Infection Biology, Berlin, Germany
C. trachomatis Serovar A & D 12 isolates from
STD cases
Dr. Sudha Salhan, Department of Obstetrics and Gynaecology, Vardhman Mahavir
Medical College and Safdarjang Hospital, New Delhi, India.
Mycoplasma spp. 8 Department of Microbiology AIIMS, New Delhi, India.
Chlamydia pneumoniae 5
Candida spp.1 0
Ureaplasma 11
Pseudomonas aeruginosa 2
Klebsiella pneumoniae 2
Acinetobacter baumannii 2
Staphylococcus aureus 2
Herpes simplex virus 1(HSV-1) and
Herpes simplex virus 2 (HSV-2)
2
Cytomegalovirus 2
BK virus 2
Trichomonas spp. 8 Department of Microbiology AIIMS, New Delhi, India & Department of Poultry Science,
University of Georgia, Athens, USA.
Neisseria gonorrhoeae 2
Neisseria meningitidis (genital isolates) 3 Prof. J. W. Tapsall, WHO Collaborating Centre for STD and HIV, Department of
Microbiology, The Prince of Wales Hospital, Randwick, New South Wales, Australia.
Neisseria lactamica 94D4 1
Neisseria sicca 94C1 1
Neisseria subflava 86G7 10
Patel et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:24
http://www.ann-clinmicrob.com/content/9/1/24
Page 4 of 10pain (32.0%), infertility (4.3%) and other STD related
symptoms. In our study overall prevalence of STD
among females with STI related symptoms was 21.2%
(593/2800). STI was more common among patients in
the age group of 18-33 years (391/567). In an earlier
study, STI prevalence was found to be 16.2% among
patients attending STD clinics at a regional STD centre
at New Delhi [24]. A relatively high prevalence (36.5%)
of STI is reported in tribal population of central India
[25]. In a study from Surat, 47.5% of female sex workers
were reported to have STI [8], while in Calcutta 59.0%
sex workers had STD [26]. In the present study, genital
chlamydial infection, as detected by Roche Amplicor
test, DFA and in-house PCR assay, was 25.2% among
the symptomatic females enrolled. Although C. tracho-
matis prevalence in patients of different age groups was
not significantly different (Figure 1), more than 92.0%
(118/128) of the total patients positive for C. trachoma-
tis were from reproductively active age group of 18-41
years. During the course of the study (2003-2009), the
prevalence of patients infected with C. trachomatis ran-
ged from 24.0% to 30.0% (Figure 2). Among female sex
workers in Surat, India, the prevalence of genital chla-
m y d i ab yP A C E 2t e s tw a sf o u n dt ob e8 . 5 % ,w h i l ei n
Ahmedabad, India it was reported to be twice as much
[8]. Among the tribal populations (patients/general
population) from central India although STI was high
(36.5%), only 4.0% chlamydial infection is reported [24]
which is similar to that observed among patients in
Azerbaijan 3.1% [27] and Bangladesh 3.4%, [28]. High
chlamydial infection has also been reported in Manila
23.3%, Cebu, Philippines 37.0% and 14.0% in Nicaragua
[21,29].
Specificity and sensitivity of primers
Using the BLAST program from NCBI, gyrA gene of C.
trachomatis (Entrez GeneID: 884941) was selected for
primer designing. Amplicons of desired size (463-bp)
were obtained when purified genomic DNA of different
serovars of C. trachomatis ( A ,Da n dL 2 )w e r eu s e da s
templates for the in-house PCR, while no amplicon was
detected when genomic DNA from humans as well as
other STD causing and related microorganisms were
tested as templates. The specificity was further con-
firmed by sequencing the amplicons obtained from
10.0% of positive clinical samples. The DNA sequence
of the amplicons were aligned to the known sequences
of serovars A, B, D, E, G, L2 and Sweden2 of C. tracho-
matis in the GenBank databases (Additional file 1). The
primer pair was highly sensitive as an amplicon could
be seen when as low as 10 fg of purified chlamydial
genomic DNA (equivalent to 9 IFUs) was used as tem-
plate (Figure 3). C2/C5 primers amplified the target
sequence even when crude lysates of clinical samples
were used in the PCR reaction.
NAAT based diagnosis has been observed to be signifi-
cantly more sensitive than conventional methods such
as culture and antigen based methods for diagnosis of
C. trachomatis in clinical specimens. Several existing
PCR assays including the Roche MWP test target the
cryptic plasmid while the chromosomal targets most
widely used are ompA and rRNA coding genes [20-35].
Plasmid based PCR detection assays are considered to
be more sensitive compared to chromosomal gene based
assay, as plasmid copy number is generally 7 to 10 per
Figure 1 Prevalence of C. trachomatis infections by age group;
age range from 18-51 years and above.
Figure 2 Prevalence of C. trachomatis infections by year (2003-
2009).
Figure 3 Sensitivity of in-house primers using purified
chlamydial genomic DNA. PCR amplification of purified genomic
DNA (100 ng to 1 fg) of C. trachomatis serovar D was carried out by
using C2/C5 primers.
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AMPLICOR CT (Roche Diagnostic system) and Ligase
chain reaction kit from Abbott (presently out of market)
were shown to be highly sensitive (92.9 to 100%) and
specific (99.0 to 100%) for C. trachomatis detection
[3,39-42]. However, major obstacle in adopting these
kits for routine diagnosis in clinical laboratories in India
is their high cost (average cost of single assay is $50). It
may also be emphasized that the commercially available
diagnostic kits use plasmid-based amplification. A new
variant of C. trachomatis (Sweden2), carrying a 377-bp
deletion within the plasmid, was reported in Sweden
[43]. This deletion includes the target sequences used in
the commercial diagnostic assays of Roche and Abbott.
We have also observed infection due to plasmid free
variants as reported in other populations [44,45], which
remains a challenge for detection (unpublished results).
Comparison of the performance of different PCR
assays including plasmids, ompA and rDNA targets has
suggested that in general plasmid primers are 10 to
1000 times more sensitive (0.1 fg for plasmid DNA)
than the genomic DNA primers for ompA (0.1 pg to 10
pg genomic DNA) and rDNA (1 pg genomic DNA)
[34,46-48]. Our assay targeting gyrA gene showed high
sensitivity (10 fg to 0.1 pg genomic DNA) compared to
other genomic targets.
Clinical performance of in-house PCR and its comparison
with DFA and Roche Amplicor MWP kit
To check the performance of in-house PCR assay, the
samples were divided into groups as mentioned under
methods. The median age of patients for group I (274
patients) was 29 years (range: 18 to 57 years). Out of
274 patient samples, 59 (21.5%) were positive and 191
samples (69.7%) were negative both by PCR assay using
C2/C5 primer set as well as by DFA (Table 2). Out of
the 28 discrepant samples, 15 samples were considered
true positive, as 11 samples were PCR and FISH positive
but DFA negative while 4 were DFA and FISH positive
but PCR negative (Table 3). The remaining thirteen
discrepant samples were considered true negative as
they tested negative both by DFA and FISH assay.
These 13 cases, which were PCR positive, could not be
reconfirmed as follow-up specimens could not be col-
lected because the patients had received treatment.
Based on our results, it is evident that C2/C5 primer
pair detected significant number of true positive samples
(70 out of 74, p < 0.0001) as compared to the DFA
method that detected 63 out of 74 as true positive
samples.
Among the 319 samples enrolled in group II, 244 were
negative while 60 samples were positive by both in-
h o u s eP C Ra n dc o m m e r c i a lP C Ra s s a y( T a b l e2 ) .T o
resolve the discrepancy, the genomic DNA of discrepant
samples (as described under methods) was purified to
remove PCR inhibitors if any, and tested for amplifica-
tion of two housekeeping genes: ompA and plde as well
as by in-house PCR and commercial PCR method. Out
of 15 discrepant samples, 13 samples that were positive
by in-house PCR but negative by commercial PCR, 9
samples tested positive for ompA/plde and hence were
considered true positive. The remaining four in-house
PCR positive samples, tested negative for ompA and
plde and Roche PCR and were thus scored as true nega-
tives. Two discrepant samples that were positive by
Roche Amplicor MWP kit and negative by in-house
PCR, tested positive for ompA/plde and were therefore
considered true positive (Table 3). The response to ther-
apy administered to the patients with discrepant results
obtained from hospital records also supported our final
results shown in Table 3.
Once again as for group I, C2/C5 primers detected a
significant number of samples (69 out of 71, 97.0%) and
its efficiency is comparable to that of commercial PCR
assay which detected 98.0% of positive samples. How-
ever, the commercial PCR kit detected many samples
only when DNA was purified from these samples. Based
on our results, the prevalence of C. trachomatis infec-
tion was 25.5% among women visiting gynaecology out-
patient clinic when DFA was selected as gold standard
Table 2 Comparison of in-house PCR with DFA and Roche amplicor MWP kit, results for C. trachomatis before and
after discrepant analysis.
PCR results
C2/C5
After resolution of discordant results
Group I DFA Positive Negative Total Positive Negative
Positive 59 24 83 70(59+11) 13(24-11)
Negative 4 187 191 4 187
Total 63 211 274 74 200
Group II Roche
Positive 60 13 73 69(60+9) 4(13-9)
Negative 2 244 246 2 244
Total 62 257 319 71 248
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MWP kit was taken as gold standard. The overall preva-
lence of C. trachomatis was found to be 23.0% among
symptomatic patients enrolled in the study.
Sensitivity, specificity, PPV and NPV
The estimated sensitivity and specificity range of DFA is
61.0% to 92.0% and 99.0% to 100% respectively in different
laboratory settings when compared to that of culture or
non-culture methods [44]. This could be due to sample
preparation and handling conditions in the clinical set up
as well as the laboratory. To avoid such factors, the discre-
pant samples were analyzed with alternative methods of
detection in order to determine their true status. The in-
house PCR (C2/C5) primers demonstrated sensitivity of
93.6% which increased to 94.5% after resolution of the dis-
crepant cases by a second method for group I (Table 4).
Similarly, the specificity of PCR by C2/C5 primers
increased from 88.6% to 93.6% after discrepant analysis by
FISH. The positive predictive value (PPV) of in-house PCR
increased from 71.0% to 84.3% while the negative predic-
tive value (NPV) remained unchanged at 98.0% even after
confirming the status of discrepant samples. All the discre-
pant samples (see Table 3) when retested by in-house PCR
method gave 100% reproducible results. The estimates of
specificity of in-house PCR might have improved further if
the follow up samples from patients could be obtained.
The overall sensitivity of DFA in the present study was
88.0% which is close to suggested value of 92.0% [44]. In
general, the cut-off for DFA is established to get the best
combination of sensitivity and specificity, as a result,
sometimes one may miss out a positive sample by com-
promising sensitivity to achieve specificity. Thomas et al.
[33] have reported that DFA kit has its limitation as a
reference method for evaluating a new diagnostic kit or to
check inter-laboratory variation. According to their report
the diagnostic performance of DFA test is highly depen-
dent on the number of chlamydial EBs that should be seen
in order to score a sample as positive sample. Since about
30.0% of the clinical samples contain ≤ 10 EBs, they are
scored as negative. Shattock et al. [32] observed similar
limitation when they compared various detection methods
for C. trachomatis.T h u sas a m p l em a yb eD F An e g a t i v e
as it contains ≤ 10 EBs but can score positive by PCR
method. In our study we observed 28 samples out of 274
that were positive by C2/C5 primers but negative by DFA
or FISH assay. These samples, which repeatedly were posi-
tive by our PCR, may have contained chlamydial genomic
DNA, but unfortunately no follow up samples were avail-
able to confirm this as patients responded to treatment
and in some cases they did not return to the clinic.
We also evaluated our in-house PCR method against
commercially available and widely used Roche MWP kit.
It is pertinent to mention that to avoid the swab sample
variation that may occur when multiple swabs are taken
(especially when infection load is low); two swabs were
taken for each patient. We observed inhibition of amplifi-
cation reaction when internal control provided by Roche
MWP kit also did not amplify. Similar observation is
reported previously [32,48]. However, when DNA from
these samples was purified and retested by Roche MWP
kit, they were found to be positive. Compared with
Roche MWP PCR assay our in-house PCR by C2/C5
shows 96.7% sensitivity and 95.0% specificity. Subsequent
to resolving discrepancy the sensitivity of PCR method
increased to 97.1% and specificity increased to 98.4% and
the PPV of in-house PCR increased from 82.1% to 94.5%
while the NPV remained unchanged at 99.0% (Table 4).
Conclusions
The major objective of this work was to develop an in-
house PCR assay that is cost effective and has high
Table 3 Resolution of discrepant results for C.
trachomatis infection.
No. of discrepant
samples
Conclusion
C2/
C5
DFA FISH
Group I (n = 28) 11 + - + True positive
4 - + + True positive
13 + - - True
negative
Group II (n = 15) Roche ompA/
plde
9 + - + True positive
4 + - - True
negative
2 - + + True positive
A second test was applied for each sample. FISH was taken as the gold
standard for group I and ompA/plde for group II.
Table 4 Performance of in-house PCR assays based on expanded spectrum of positivity after confirmatory FISH assay
and ompA/plde PCR.
In-house PCR Assay Sensitivity Specificity PPV NPV
% 95% CI
a % 95% CI
a % 95% CI
a % 95% CI
a
Group I 94.5 86.7-98.5 93.6 89.1-96.5 84.3 74.7-91.4 98 94.7-99.4
Group II 97.1 90.2-99.7 98.4 95.9-99.6 94.5 86.6-98.5 99 97.1-99.9
a CI, Confidence interval.
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nosis of C. trachomatis infection. Despite the high pre-
valence of STI in developing countries, the laboratory
confirmation of infection is not carried out because of
poor resource settings and due to lack of simple, cost
effective diagnostic tools. The existing diagnostic meth-
ods in developing countries are not effective and their
sensitivity fall below 45.0% which leads to further spread
of infection [49]. The annual incidence of STIs in India
is about 5.0% with 40 million new cases every year [50].
This prompted WHO to emphasise on syndromic
approach for case management in developing countries
including India. A number of authors suggest that syn-
dromic management based on vaginal discharge syn-
drome either miss out a significant proportion of cases
of genital chlamydia or lead to treatment even in the
absence of infection of C. trachomatis [8,51,52]. In the
present study we enrolled patients having symptoms
and expecting treatment. In-spite of this selection bias,
the chlamydial infection was observed to be high among
females in Delhi as was evident by laboratory investiga-
tions. Quick and inexpensive diagnostic test developed
in the present study can help in regular clinical and
laboratory screening for C. trachomatis. Consistent high
prevalence of chlamydial infection as well as the poten-
tial synergistic role of STI in HIV and HPV transmission
[4-6] suggest that syndromic management along with
periodic screening may prove to be more effective
approach to achieve long term goals of STI and HIV
control through sustained access to effective preventive
and treatment services.
The principle goal of this study was to develop an in-
house PCR method that is at least as sensitive and as
specific as commercial method. An additional advantage
of the in-house PCR method would be its low cost.
Since our studies also suggest that there is a high preva-
lence of C. trachomatis (>23.0% in females visiting
gynaecology department), there is a definite need to
have a cost effective method for routine diagnosis in
India. We consider that implementation of the specific
and sensitive PCR assay, developed in the present study
may allow clinical microbiology laboratories in develop-
ing countries to detect C. trachomatis rapidly, which
would be of great consequences in disease management.
Additional material
Additional file 1: ClustalW showing the homology between
amplified sequence of DNA GyrA Subunit A in various serovars of
C. trachomatis and clinical samples. Alignment of the DNA sequences
in the GenBank database of the gyrA amplicon for serovars A, B, D, E, G,
L2 and Sweden2 of C. trachomatis.
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